This study aims to assess the relationship between KRAS mutation and HER2 expression to determine personalized targeted chemotherapy treatment for CRC patients, especially in the metastatic group, where the targeted therapy can be added after the chemotherapy or radiation therapy. Here, KRAS is linked to colorectal carcinoma.